year, Beginning We of Thanks, BD revenue with our our in which our strong, delivered XXXX diversity fiscal reflect portfolio Tom. the results action. consistent this performance. strategy and
surgical of the X.X%, our instrumentation organic delivered expectations reflects with of QX, and base impact growth total divestiture. the X% We $X.X in from base which in growth billion exceeding revenue
billion Medical full XXX BD higher was despite strong the basis BD growth growth guidance. X.X%, that organic U.S. in base revenue Asia growth single-digit in Greater China. revenue initial revenue performance year, in in $XX.X than For single-digit EMEA strong and by points Total low was growth with with revenue in X%, delivered is driven and regionally we as of America the Interventional. base high Latin mid-single-digit our Base and growth well and fiscal growth
by revenue are plus contribution portfolio driving from an our X.X% core supported spaces growth Our of targeted plus increasing side continues higher revenue durable to our the performance be profile. growth that and
XX organic for anniversaried, full the the acquisitions to about basis year. was we which points continue also tuck-in We from from benefit contribution
a target. period, strong our X%, base which of long-term drove is CAGR about well Over we a revenue X-year above organic
found Let in me be each announcement earnings now segment's into detail today's the provide presentation. some high-level insight in performance can and quarter. Further
offset Pharmaceutical with delivery Medical from Solutions BD reflects impacts medication Medication volume-based access $X.X America and growing Medical vascular management performance by This performance a Systems. North in in in billion procurement. systems revenue driven the from solutions partially was totaled China BD in performance quarter, execution strong continued by market softness fourth in in decline our X.X% through Europe including resulting dynamics, catheter some strategy. strong and Management of
of driven automation costs by both which and growth MMS workflows dispensing as and pharmacy solutions in help customers address delivered exceptional and rising improve growth efficiencies double-digit XX.X%, shortages. pharmacies on and focus labor
BD by demand solutions slowdown fourth continued double-digit of partially for of exports XX.X% delivered anticoagulants. offset $X.X Systems billion the biologics, China Life Pharmaceutical growth totaled and quarter another a driven in Sciences prefillable strong for in revenue by of quarter.
grew Excluding Biosciences. COVID-only driven testing, strong X.X% in Life by growth Sciences base revenues double-digit
growth installed X.X%, leveraging of business expanded automation base MAX based the IDS our growth lab system assays, Sciences continued instrument strong business Life COR molecular placements solution continued and Kiestra our our IDAST BD IVD BD microbiology by reflects growth and base. and driven of BD of adoption
BDB Growth an by recovery strong prior demand management year. the in and was COVID-related the and our solution of XX.X%, that grew by BD partially and across immunology, of customer researchers new Cells to specimen enabling biology. launched FACSDiscover stocking integration prior use a biological decline level cancer is offset entirely comparison like that year speed, driven ease and cell recently by for distributor depth in of for was in China research driven Sorter SX fields
$X.X percentage growth the of organic driven organic of fourth billion BDB's in points. from totaled was growth leveraging revenues FACSDuet or reflects platform of divestiture automation. also of in double-digit our XX.X% surgical and clinical increasing base BD strong Interventional X.X% instrumentation The the organic. XX.X% strong and the quarter, growth analyzers which installed surgery FACSLyric growing performance reagents, the impact by X% excludes XX.X
repair PI reflects reflects hernia of portfolio products for of performance our by and Phasix disease our market driven portfolio and vascular demand peripheral our reconstruction system which in prevention advanced strong XX.X%, atherectomy penetration our venous leading infection ChloraPrep growth grew and solution. in rotor the adoption Organic strong in global strong China.
in a ERP new chronic settings. by aided for demand alternative was by in strong and fiscal care distribution acute stabilization grew both our EMEA in continued the Urology solutions improved following XX.X%, care incontinence 'XX. primarily implementation PureWick Growth supply driven and
of points P&L. basis and increased points. up margin QX to on improvement operating we anticipated, as strong XXX our to of diluted currency-neutral XX% adjusted XX% reflects Gross with moving margin of very XX.X%, basis. delivered double-digit strong Now a margin or EPS basis $X.XX growth adjusted XX.X%, XX
margin R&D year's percent a expected, expense As improvement investment due ability profit driven to to leverage our was on performance, moderated to sales driven reinvestment. of by inflation simplification initiatives, strong offset our favorable outsized revenue our comparison SSG&A last timing COVID by and a as lower
includes of XX% Full original delivering or year $X.XX an versus currency This diluted X.X% guidance. our $XX.XX of neutral. grew adjusted earnings EPS currency-neutral additional
Additionally, base growth currency-neutral with points reduced we EPS approximately associated of XX%. almost absorbed COVID-only XXX basis testing, combining
year For the site sold. margin from and was of the recorded our excluding impact benefit was of accounting income full basis year. XX.X% other absorbing over up EPS. basis offset with XXX points the the exceeding Operating margin employee point year, prior XXX in goal XX The goods an item XX no when inflation G&A benefit-related to points impact the in points treatment of of item, flat basis to gross employee or for about is is resulting and basis to margin XX.X% of outsized cost fully
at goals, in support delivering will fiscal programs While our we our and of also R&D profile sales investment 'XX beyond. about X% year margin maintained strong that innovation pipeline of billion advance our $X.X or in growth to
our made anticipated, pre-pandemic progress achieving significant we've towards goals. As margin improvement
of outsized adjusted margin X is or spin overcoming basis inflation XXXX particularly years. adjusted XXX past includes it in given almost the billion our of 'XX FY ahead margin which significant is Our points $X operating
to margins. remain next well targeted our years, positioned XX% we the operating to return X Over
in approximately from 'XX. our Cash and totaled billion operations Regarding $X flows FY allocation. cash capital
accelerated the back in strongest focused free $XXX working was flow FY due continued on of cash cash over million. of to inventory our We balances. capital, QX cash flow over with free as expected, and anticipated, half 'XX the year in a remain As step-up including normalization by delivered conversion of increasing and moderation flow
Alaris inventory We increase duration are planning to be through the 'XX investments and end another and offset will step cash around of in through achieved by free This both reduction CapEx flow we more of double the further digits. and support improvement to FY of investments expect the continued levels targeted areas to cash year focused of which discipline expect prioritization than remediation.
execute achieve around strategy, XXXX well BD As against target our remain cash of long-term we we positioned to conversion our XX%.
Beyond down our we our in investments this billion X.Xx. and dividends. of debt a with million strongest capital ratio position We over us net categories balance in in net investment $XXX paid This through positions billion in through M&A year of to growth, on FY and shareholders year returned ended the fiscal our well leverage strategy. higher-growth leverage $X.X cash 'XX, capitalize to which tuck-in to is accelerate opportunities since $X.X our
to Moving for guidance fiscal our 'XX.
For found be underlying our the also your guidance presentation. in assumptions can detailed convenience, our
over strong deliver the has our performance in BD ability by to demonstrated challenging As the years, past X results the times. most
our and all cost and optimized capital Our of bold, agility. decisions, performance allocation diversified our our further strong our execution with outsized simplification reflects improvement programs the portfolio durable execute investment XXXX and strategy, to of by benefit ability BD and purposeful
profile I'm outlined. of we share to earnings And committed plus the our has we the to at expect year guidance, revenue midpoint profile. growth another previously evolved X.X% 'XX, call, last landscape our since look pleased the our deliver of organic while we of remain fiscal we to macro growth As to
contemplated and Let some our key guidance. of the puts me share takes in
parts in First, business. we our momentum many see of strong
the or single in our include finally, portfolio Claire our that benefiting now We we pharmacy our and areas sales over disease incontinence to business, urinary recent totaling PureWick strong bioscience from trends high pre-fillable biologics; including supported pump; platform; infusion, peripheral Systems farm These and Delaris platforms. key growth. business; have our $X franchise; systems of automation billion Management molecular to our our which X deliver by syringes, the double-digit our given vascular diagnostic Medication XX% expect are in
war to deliver risk in us and and of along the despite result some heightened Middle in geographies. macro affecting dynamics results notably East allows strong the industries, most the This with increasing China, complexity many other as
in focused pressure our care resilient BD's in has And Specific elevated working remain our of on care to more efficiencies. of the proven to to health to environment, management, ecosystem be processes continue portfolio and the drive and inflation cost dynamics. providers the capital transform given ability health industry, in while this labor care health and role feel type they very essential
headwind in our of is reduced the As anticipate softness we we some customers predominantly and and these slow. market business China it Chinese relates pharmaceutical in BD, systems macro business demand our levels procurement along impacting from increased to business, largest volume-based where as dynamics our see export with impact MDS
organic provided to FY of a these down midpoint, point are We we on is base our X% with X.X% Taking This range. in growth As to X.XX% the the XX organic growth result, China midpoint the to which expect million earnings basis a deliver growth 'XX, revenue creates nearly be expect flat total this about year. reported to in to the growth consistent which to year factors points. projecting $XX headwind into over modest to of still we basis from within step last we this our and our at testing result brings of view COVID-only call. to account, growth a our X.XX% headwind organic XX
guidance. that our give we context Effective simplify the organic growth significant COVID-only unless longer will However, market. it important to COVID-only change testing help To no with our reporting year, excludes a be there's testing reporting, us initial in was this base
the currency-neutral that to XX growth growth in reminder, QX FY X.X% X.X%. platform organic impact not impact does sale of revenue surgical FY point accounted is to have and nearly basis 'XX revenue of our total the total closed a will our in guidance a in 'XX instrumentation while As growth for
deliver adjusted to reported generating progressing earnings. year our profile. flat including we strong margin, while expect to year-over-year towards of approximately on support 'XX and to FY XX% growth plan including and We reliable a basis points. basis, margin growth, of our Moving impact cash of On another improvements operating gross currency our goal flow headwinds to margins and of strong the be about XX
we simplification with basis Excluding than gross another further we strategy offsetting points from that margin will reduction and of and in our moderate expect FY to headwinds improve more end about to XX XXX points the currency, points basis flow. of basis from efforts plan inventory inflation of impact XXX by occurred the down 'XX which improve that of cash FY outsized 'XX,
simplification be to SKU from by network programs. value driven The Recode continue simplification programs operating and model our rationalization optimization,
lean Excellence Additionally, of which program, productivity principles driving application on gains across operations. our focuses is our BD the
As performance on leverage from and it OpEx, operating revenue anticipate model strong simplification benefit expense programs. to we SG&A continued our pertains
pipeline, is After in needed at advance will R&D a years anticipate to over that investing result leverage. consistent X modest our average, dollar R&D consecutive in of year-to-year X% 'XX, in we spend some which on FY
we XX% adjusted margin in XX operating 'XX, achieve driven us result, a points by basis to around on by track on our leverage. reported XX.X% margin FY reported This well primarily over goal a As FY SSG&A expect the by 'XX. basis puts to improve
between tax adjusted to no rate changes, legislative For XX%. we be or major tax, our and effective assuming expect XX% regulatory
timing discrete it of not our given tax items. for As basis a rate reminder, on to be a the unusual would fluctuate quarterly
the EPS basis This X.XX% at considerations, a of adjusted or double-digit includes to the instrumentation divestiture within excluding midpoint. currency these from a X.XX% expect surgical the impact earnings divestiture the to all and of as approximately XX.XX% midpoint XX%. and of a range growth growth, XX the XX% we of headwind result, absorbing before point Given the business at X% implies of about
me estimated the walk Let from impact you through now currency.
headwind faced translate with As currency-neutral of but discussing including dollar, consistent a from our we currency performance, our in on to and to a inventory best reported normal stronger of the their U.S. current our underlying a impact as our perspective reminder, FX provide currency we fluctuations footprint, represent and our other accounting with for and what basis using we in timing we are business spot are network. the results outlook, translation, on a production companies sourcing, forward P&L, manage currency guidance global to along provide also impact distribution manufacturing the movements throughout rates, given
Since nearly and change over call for dollar our against X/X significantly major strengthened the last expected period this U.S. of impact. the accounts the most in time FX August, currencies,
in relates sourcing it the last by about weakened footprint, where the months X the 'XX achieving the first of been October taking versus ending seen that have year the to X over average in that rate peso versus timeframe with a as Mexico, Additionally, X have over from fiscal the we not peso average rates peak in months dollar over the well manufacturing years. large XX%,
growth to the $XX, $XX.XX XXX EPS EPS billion in, $XX.X total X% estimated year full approximately a to to basis. to be of growth approximately $XX.X to be on points we to current approximately expect and impact currency, between revenues of represents basis company adjusted of X.X%. XX on which a Based currency revenues a estimated be of spot rates, in adjusted range for basis including to is headwind to illustrative All purposes, and billion points
fluctuate time, CAGR from of is X.X% that which As profile deviate a delivering it over base organic about be consistently reminder, currency not well growth, in profile. investment our prudent is organic above our growth expected an strong base plus resulting X.X%, can X-year and would to
rate X.Xx in of growth. And margin our expect improvement, with the focus flow deliver cash cash sales. conversion, to earnings continue growing We we to on improved resulting deliver free double-digit
of index following for 'XX will considerations how are fiscal in As through revenue and the margin context you QX year. phasing, think the of the on remainder
we the $X.XX about full we versus to As EPS of a organic revenue year under-index $X.XX. and growth expect prior XXX it adjusted year by QX, over to basis relates to points, in decline expect the
There are consider. to items X key
with driven impact a First, IDS and and are farm China. base sales equally market by is business the prior and impacts with modest testing systems These about along dynamics the year comparison, with MDS the COVID-only associated weighted in primarily in China. impact respiratory
also the over the expect second ramp Alaris weighted be revenues to and half. year We to
Second, decline basis with from driven inventory-related offset basis reductions, through we the expect overcoming absorption our we inflation. our outsized inventory basis from which XXX to basis in mitigation a cost QX points points negative initiatives XXX also margin operating by simplification points while on by around reported to impact planned and partially dynamics expect and another XXX FX
Lastly, of a item tax creates in QX had that year we comparison. discrete negative a last
the to in than about higher think you the by Alaris. half, growth ramp-up be remainder partially our As second sales full the driven of expect of organic year year, we the range
on We significantly margins reported being QX resulting slightly basis. flat in on or basis, expect operating margin on nearly a to a a year-over-year sequential up our currency-neutral expand basis
for closing, are very our in significant The year, macro pleased durable past our to year another inflationary we complexity momentum performance ability given and our In along this FY strong and navigate us particularly long-term portfolio, with with of and pressure. our to our track our create our this stakeholders. confidence delivering executing momentum continue value of against all into successfully ability and of record commitments, 'XX gives in
assemble that, to an purpose BD, take employees delivering Operator, commitment unwavering talented mindset queue, a session. start who this our to With me let's you are Let the our please? moment across performance. Q&A through can and core to thank growth our
